Curevac announces changes of cdo - myriam mendila to succeed klaus edvardsen

Myriam mendila appointed as chief development officer starting from february 1, 2023 klaus edvardsen returning to denmark after holding numerous leadership positions in the u.s. and europe ulrike gnad-vogt, senior vice president area head oncology, will act as interim chief development officer tÜbingen, deutschland and boston, ma / accesswire / june 8, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna") today announced that chief development officer klaus edvardsen will leave the company on june 30, 2022.
CVAC Ratings Summary
CVAC Quant Ranking